Sinovac to trial COVID-19 vaccine in South African children in global study
China's Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Sinovac and local partner Numolux Group said on Thursday.
- Country:
- South Africa
China's Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Sinovac and local partner Numolux Group said on Thursday. The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement.
The global trial will enroll 14,000 participants across Chile, the Philippines, Malaysia, Kenya including 2,000 in South Africa, they said. The trial has been approved by South African drugs regulator SAHPRA, and the first child will be vaccinated at the MeCRU Clinical Research Unit based at the Sefako Makgatho Health Sciences University on Friday.
"The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents ...efficacy will also be evaluated against hospitalisation and severe COVID-19," Sinovac and Numolux said.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Commencement of Nomination Process for Phase 3 of Lok Sabha Elections
Nomination process underway for 4 Lok Sabha seats in Assam in third phase
Toshiba receives order for geothermal power plant equipment renovation in Kenya
At least a dozen killed and an estimated 15,000 displaced by flooding in Kenya
LS elections: Poll parties of first phase airlifted in advance in J-K’s Kishtwar